Report recommends FDA revises postmarketing processes

By Nick Taylor

- Last updated on GMT

Following a review of the backlog of postmarketing studies the FDA has initiated changes to improve its processes, including developing Manuals of Policies and Procedures (MAPP) to track the status of trials.

By law the US Food and Drug Administration (FDA) must initiate an annual review of postmarketing backlog because in recent years concerns were raised about the number of trials listed as pending.

The review was performed by Booz Allen Hamilton. In total 1531 open postmarketing studies were reviewed, of which 80 per cent are proceeding according to the established timelines, have been submitted for FDA review, have met their goals or are no longer needed.

Having assessed the status of the reviews the report made a number of recommendations. The FDA is evaluating these and has begun initiating changes based on the results of the review.

In addition to developing new MAPP the FDA has established a postmarketing study coordinator and tracking coordinator within each new drug division. Furthermore, the agency has created a postmarketing study database to improve data capture, tracking and generate reports.

Further recommendations

The report makes nine recommendations about how the FDA can improve its postmarketing processes. These include ensuring that post market requirements (PMR) and commitments (PMC) are written to meet specific objectives.

In addition the report calls on the agency to establish specific study start and final report submission milestone dates, to inform sponsors not to wait indefinitely on protocol feedback and capture actual dates of milestone completion.

By implementing these measures, and the others detailed in the report, the authors believe the FDA can reduce the size of the PMR/PMC backlog, help complete them on-schedule and improve tracking.

The complete report can be found here​.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us

Products

View more

Webinars